Â黨¶¹´«Ã½¾çÎâÃÎÃγöÑݵÄÓм¸²¿µÚ10¼¯ÔÚÏßԢĿÃâ·Ñ..."/> ÉÏÆûͨÓÃÏÈÆÚÓñð¿ËºÍ¿­µÏÀ­¿ËµÄ²¿·Ö³µÐÍ×öÁËʵÑ飬³¢µ½ÁË¡°Ò»¿Ú¼Û¡±´øÀ´µÄÏúÁ¿ÌðÍ·ºó£¬½üÆÚÓÖ½«Ö÷Á¦³µÐÍCT5¼ÓÈëµ½¡°ÏÞʱһ¿Ú¼Û¡±µÄÕóÓª¡£Ð¿îCT5ÉÏÊÐÒÔºó£¬ÏÞʱһ¿Ú¼ÛΪ21.59ÍòÆð£¬Ïà±ÈÔ­³µ¼ÛÓÅ»ÝÁ¦¶ÈºÜ´ó£¬¸üÀëÆ×µÄÊÇпîCT5ÈëÃż´¸ßÅ䣬ÉÐÓС°Õ½Ëð»ØÑªÀñ¡±£¬¼´³µÁ¾µ¥´Î¶¨Ëð³¬Èý³É¼´¿ÉÃâ·ÑÖû»µÈ¼Ûгµ¡£"/>

ÌÚ²©tengbo9885¹ÙÍø

Â黨¶¹´«Ã½¾çÎâÃÎÃγöÑݵÄÓм¸²¿µÚ10¼¯ÔÚÏßԢĿÃâ·Ñ...

Â黨¶¹´«Ã½¾çÎâÃÎÃγöÑݵÄÓм¸²¿µÚ10¼¯ÔÚÏßԢĿÃâ·Ñ...

¡¶Â黨¶¹´«Ã½¾çÎâÃÎÃγöÑݵÄÓм¸²¿µÚ10¼¯ÔÚÏßԢĿÃâ·Ñ...¡·¾çÇé¼ò½é£ºÉÏÆûͨÓÃÏÈÆÚÓñð¿ËºÍ¿­µÏÀ­¿ËµÄ²¿·Ö³µÐÍ×öÁËʵÑé³¢µ½ÁËÒ»¿Ú¼Û´øÀ´µÄÏúÁ¿ÌðÍ·ºó½üÆÚÓÖ½«Ö÷Á¦³µÐÍCT5¼ÓÈëµ½ÏÞʱһ¿Ú¼ÛµÄÕóÓªпîCT5ÉÏÊÐÒÔºóÏÞʱһ¿Ú¼ÛΪ21.59ÍòÆðÏà±ÈÔ­³µ¼ÛÓÅ»ÝÁ¦¶ÈºÜ´ó¸üÀëÆ×µÄÊÇпîCT5ÈëÃż´¸ßÅäÉÐÓÐÕ½Ëð»ØÑªÀñ¼´³µÁ¾µ¥´Î¶¨Ëð³¬Èý³É¼´¿ÉÃâ·ÑÖû»µÈ¼ÛгµÕÐÄý±¾¾ÍÊÇÊÔË®Á¶³öÒ»ÖØ½ûÖÆºó´ø×ÅЩÐíÐ˷ܽ«¾«¸Ö½£Õٻؾ«¸Ö½£³¤Èý³ß¿íÁ½´çºñÔ¼Ò»·ÖÓÐÓ೤½£¼â¶ËÁ½´ç´¦ÝëµØÊÕ½ôÏ÷³ö½£¼âÂ黨¶¹´«Ã½¾çÎâÃÎÃγöÑݵÄÓм¸²¿µÚ10¼¯ÔÚÏßԢĿÃâ·Ñ...Åж϶Է½¾¿¾¹¶ÔÄãÊDz»ÊÇÖÁÐÄ¿ÉÒÔ¿´ËûÊDz»ÊǺã¾ÃÖ÷ÒåÕß

¡¶Â黨¶¹´«Ã½¾çÎâÃÎÃγöÑݵÄÓм¸²¿µÚ10¼¯ÔÚÏßԢĿÃâ·Ñ...¡·ÊÓÆµËµÃ÷£º½âÃÜ£ºNSCLC¸÷Çý¶¯»ùÒòµÄ×éÖ¯ÐÎÌ¬ÌØÕ÷2018-01-08 23:19¡¤Á¼Ò½»ã×÷ÕߣºÕÅС¹Ë ȪԴ£ºTumorTalk¼ÇµÃÒ»¾­Ìýµ½²¡Àíҽʦ˵¹ýÒ»¾ä»°¾µÏ¿´×ÅÕâ¸ö±ê±¾ÏñÓÐEGFRÍ»±äÆäʱÒÔΪÄÉÃÆÕâÊÇÔõô¿´³öÀ´µÄ×î½ü¶Áµ½¼¸ÆªÎÄÕÂÖÕÓÚ°ïÎÒ½âÁË»íÔ­À´·Î°©Öвî±ðµÄÇý¶¯»ùÒò³ýÁËÁÙ´²²¡ÀíÌØÕ÷»¹¶¼ÓÐÆæÒìµÄ×éÖ¯ÐÎÌ¬ÌØÕ÷£¨histopathological features£©EGFRÍ»±ä³ýÁË×î³£¼ûÓÚÅ®ÐÔ²»ÎüÑ̵ÄÏÙ°©»¼ÕßÖÐÉÐÓÐÄÄЩ×éÖ¯ÐÎÌ¬ÌØÕ÷ÄØÑо¿ÏÔʾEGFRÍ»±ä³£¼ûÓÚÈéÍ·×´(papillary)¡¢Î¢ÈéÍ·×´(micropapillary)¡¢ÏÙÅÝÑù(acinar)¼°Åß²ã×´(lepidic)µÄ×éÖ¯ÐÎ̬ÖоßÓÐЬ¶¤Ñùϸ°û{hobnail cell type}¼°ºËÄÚÈÝÄÉÌå(intranuclear inclusion)[1]ÈçÏÂͼËùʾ£ºKRAS»ùÒòÒ²ÊÇNSCLC»¼ÕßµÄÇý¶¯»ùÒòÆäÍ»±ä³£¼ûÓÚÎüÑ̵ÄÏÙ°©»¼ÕßÖÐÑо¿ÏÔʾ£ºKRASÍ»±äµÄ×éÖ¯Ñ§ÌØÕ÷ÒÔʵÐÔ×éÖ¯(solid histology)¼°Ö×Áö½þÈóÐÔÑ×ÐÔϸ°û£¨tumor-infiltrating inflammatory cells£©ÎªÖ÷[2]KRAS¼°EGFRµÄÇø±ðÈçÏÂͼËùʾ£º×Ý×ø±ê´ú±í²î±ðÍ»±äÀàÐÍÖ×ÁöÖи÷×éÖ¯ÐÎ̬µÄÁ¿´ÓͼÖпÉÒÔ¿´³öKRASÍ»±äµÄÖ×ÁöÖв»±£´æÅß²ã¼°Ï¸Ö§Æø¹Ü·ÎÅݰ©×éÖ¯ÐÎ̬£¨lepidic/bronchioloalveolar )EGFRÍ»±äµÄÖ×ÁöÖв»±£´æÊµÐÔ×éÖ¯ÀàÐÍ£¨solid)ÈçͼÖкìȦËùʾ¶øKRAS¼°EGFRÍ»±ä¾ù¿É±£´æÓÚÈéÍ·×´¡¢Î¢ÈéÍ·×´¡¢ÏÙÅÝ×´¼°»ìÏýÀàÐ͵Ä×éÖ¯ÐÎ̬ÖÐNSCLCÖеÄÁíÒ»¸öÇý¶¯»ùÒòALKÈÚºÏÖ÷Òª±¬·¢ÔÚÄêÇáµÄ²»ÎüÑ̵ÄÏÙ°©»¼ÕßÖÐÑо¿ÏÔʾ£º±¬·¢ALKÈںϵÄÖ×Áö×éÖ¯ÐÎÌ¬Ñ§ÌØÕ÷Ö÷ҪΪ¾ßÓÐÓ¡½äϸ°û(signet ring cell)»ò¸ÎÑùϸ°û(hepatoid tumor cells)³Êɸ״ÐÎ̬(cribriform patterns)ÉøÍ¸ð¤ÂѰ×(mucin production)[3]ÈçÏÂͼËùʾ£ºALKÑôÐÔ¼°ALKÒõÐÔ×éÖ¯ÐÎ̬ѧ¶ÔºÃ±ÈϱíËùʾ£ºÕâ¾ÍÊÇΪʲô²¡Àíҽʦͨ¹ý¾µÏÂϸ°ûÐÎ̬¾Í¿ÉÒÔ˵³öÏñÊÇÓÐij»ùÒòÍ»±äµÄÔµ¹ÊÔ­ÓÉÁËÏàП÷ÈË¿´µ½ÕâЩµÄͬʱҲÄܸÐÊܵ½²¡ÀíµÄΰ´óÖ®´¦µ«Ò²ÈçÎÄÕÂÖÐËù˵ÐÎ̬ѧɸѡ²»¿É×÷ΪΨһָµ¼ÓÃÒ©µÄ±ê×¼»¹ÐèҪ͎á·Ö×Ó¼ì²âÀ´½øÒ»²½È·¶¨»ùÒòµÄÍ»±ä״̬ÒÔ¸øÓ軼Õ߸ü¾«×¼µÄÖÎÁƼƻ®²Î¿¼ÎÄÏ×1. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009; 63: 235-40.2. Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 2013; 26: 1307-19.3. Nishino M, Klepeis VE, Yeap BY, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 2012; 25: 1462-72.Ïàʶ¸ü¶à¾ÛÁ¦¹¥¼á¶¼»á¸üмá³Ö²ð¡¢½¨¡¢ÕС¢¹Ü²¢¾Ùͳ³ïÊ©²ßÎÈÍ×Íê³ÉµØÌº³§¡¢Óý²ÅËÞÉáÕ÷ǨÖØµã³å´ÌÒѸüеؿé¹ÒµØ¿ª¹¤ǧ·½°Ù¼ÆÆÆ½âÏîÄ¿ÂäµØÇ°µÄÆ¿¾±ÖÆÔ¼Íƶ¯2¸öÏîĿ˳Ë쿪¹¤Å©¿ÆÔº¡¢Ë®ÀûÐ¡ÇøµÈ3¸öµØ¿é½ü200ĶÍÁµØÍê³ÉÕÐÅĹÒ¼ÓËÙîӽ𳧵ؿ顢Öþ·»úе³§µØ¿éÍê³É¹ÒµØÕªÅÆ

±à¾ç£º
¸üУº

2025-09-24 15:02:47

±¸×¢£º
¹úÓï
ÆÀ¼Û£º
Â黨¶¹´«Ã½¾çÎâÃÎÃγöÑݵÄÓм¸²¿µÚ10¼¯ÔÚÏßԢĿÃâ·Ñ...
Ê×Ò³
Ó°Ï·
Ò»Á¬¾ç
×ÛÒÕ
¶¯Âþ
APP
ÍøÕ¾µØÍ¼